A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Study Identifier:
BO41423
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Hoffmann-La Roche
Collaborator:
N/A
Study Contact Information:
N/A
Unmapped

Study Details

Medical Condition
  • Hemophilia A Without Inhibitor(s)
  • Hemophilia A
Study Drug
  • Drug: Emicizumab
Date
Feb 2020 - Oct 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information

Protocol Summary

This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

Trial Locations

Location
Status
Location
Childrens Hospital LA
Los Angeles, California, United States, 90027
Status
N/A
Location
Hemophilia of Georgia Center for Bleeding & Clotting Disorders
Atlanta, Georgia, United States, 30308
Status
N/A
Location
Indiana Hemophilia & Thrombosis center
Indianapolis, Indiana, United States, 46260
Status
N/A
Location
University of Michigan, C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States, 48109
Status
N/A
Location
Washington Institute for Coagulation
Seattle, Washington, United States, 98101
Status
N/A
Location
Cliniques Universitaires St-Luc
Bruxelles, Belgium, 1200
Status
N/A